Sun Capital Surpluse from 2010 to 2024
| SUNPHARMA | 1,734 15.20 0.87% |
Capital Surpluse | First Reported 2010-12-31 | Previous Quarter 10.7 B | Current Value 10.2 B | Quarterly Volatility 3.6 B |
Check Sun Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sun Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 B, Interest Expense of 1.5 B or Total Revenue of 501.5 B, as well as many indicators such as . Sun financial statements analysis is a perfect complement when working with Sun Pharmaceutical Valuation or Volatility modules.
Sun | Capital Surpluse |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sun Stock Analysis
When running Sun Pharmaceutical's price analysis, check to measure Sun Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sun Pharmaceutical is operating at the current time. Most of Sun Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sun Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sun Pharmaceutical's price. Additionally, you may evaluate how the addition of Sun Pharmaceutical to your portfolios can decrease your overall portfolio volatility.